| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
Understanding the factors underpinning AI acceptability will be vital for medical institutions to
pinpoint areas of deficiency and improvement within their AI implementation strategies. |
Artificial Intelligence In Medicine 147 (2024) 102698
Understanding the factors influencing acceptability of AI in medical
imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Reduces the speed of diagnosing |
|
This is especially so for the radiology discipline which has been at the
pioneering forefront of innovating and introducing AI in medical practice
compared to other imaging fields [1]. Studies indicate that the
average radiologist needs to interpret an image every three to four
seconds in an eight-hour workday to satisfy workload requirements and
that it is unlikely this onerous workload will stabilise or decline in the
foreseeable future |
Artificial Intelligence In Medicine 147 (2024) 102698
Understanding the factors influencing acceptability of AI in medical
imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy, technology receptiveness; system
usage factors (human-computer interaction and user experience
concerns) entailing value proposition, self-efficacy, burden, and workflow
integration |
Artificial Intelligence In Medicine 147 (2024) 102698
Understanding the factors influencing acceptability of AI in medical
imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
System understanding |
|
Thematic analysis was conducted on this
collected data to answer the research questions, identify knowledge gaps
in the literature, |
Artificial Intelligence In Medicine 147 (2024) 102698
Understanding the factors influencing acceptability of AI in medical
imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Influences AI's diagnostic accuracy |
|
|
Artificial Intelligence In Medicine 147 (2024) 102698
Understanding the factors influencing acceptability of AI in medical
imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
the Dimension
of Trust (DOT) model which focuses on how acceptability is established
based on the perceived capabilities of a technological system and the
degree to which users understand and view it as beneficial [52]; the
Barriers and Facilitators Assessment (BFA) framework which evaluates
the relevance of key factors influencing successful implementation of
technologies in preventive healthcare contexts based on the characteristics
of the innovation, patients, healthcare professional, and use case
context [53]; the integrated Theoretical Domains Framework (TDF) and
Capabilities, Opportunities, and Motivations influencing Behaviours
(COM-B) model which focuses on the psychological factors governing
behavioural responses and change |
Artificial Intelligence In Medicine 147 (2024) 102698
Understanding the factors influencing acceptability of AI in medical
imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
None of the above |
|
|
Artificial Intelligence In Medicine 147 (2024) 102698
Understanding the factors influencing acceptability of AI in medical
imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
literacy, and technology receptiveness;
system usage factors entailing value proposition, self-efficacy, burden, and workflow integration; and socio-
organisational-cultural factors encompassing social influence, organisational readiness, ethicality, and
perceived threat to professional identity |
Artificial Intelligence In Medicine 147 (2024) 102698
Understanding the factors influencing acceptability of AI in medical
imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
|
Artificial Intelligence In Medicine 147 (2024) 102698
Understanding the factors influencing acceptability of AI in medical
imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
proceedings,
and dissertations in English. Studies were only included if they
were a primary study reporting on the acceptability of AI among medical
professionals in healthcare imaging domains and the factors influencing
it. Those which investigate proceedings,
and dissertations in English. Studies were only included if they
were a primary study reporting on the acceptability of AI among medical
professionals in healthcare imaging domains and the factors influencing
it. Those which investigate |
Artificial Intelligence In Medicine 147 (2024) 102698
Understanding the factors influencing acceptability of AI in medical
imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Cell replacement therapies for Parkinson’s disease (PD) based on transplantation of pluripotent stem cell- derived dopaminergic neurons are now entering clinical trials. |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
STEM-PD shows no adverse effects or tumor formation in rats up to 9 months
d STEM-PD grafts innervate correct brain regions and reverse motor deficits in rat PD model
|
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
STEM-PD shows no adverse effects or tumor formation in rats up to 9 months |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
Here, we present quality, safety, and efficacy data supporting the first-in-human STEM-PD phase I/IIa clinical trial along with the trial design. |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
GMP manufacturing of cryopreserved dopamine progenitor cell product STEM-PD from hESCs |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
STEM-PD shows no adverse effects or tumor formation in rats up to 9 months |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
GLP safety testing in nude rats shows no adverse effects and no biodistribution outside the transplant region
To assess the safety profile of STEM-PD cells prior to use in the clinical trial, we performed a 39-week toxicity, tumorigenicity, and biodistribution study of STEM-PD batch #3 in immunodefi- cient athymic nude rats under full GLP conditions. |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
FOXA2 and OTX2 |
|
Batch #3 showed a purity of 98.7% FOXA2+/OTX2+ cells |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They initiate apoptosis. |
|
SHH) for ventralization to obtain VM progenitor cells (Figure 1B; STAR Methods).27 At day 9, fibro- blast growth factor 8b (FGF8b) expressed at the midbrain-hind- brain boundary was added to fine-tune patterning toward a caudal VM fate, which we have shown to be associated with successful graft outcome in a preclinical rat model of PD.17 |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Development of new cognitive abilities |
|
|
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|